13F Pro

SEC Form 4 reporting owner

Kulkarni Samarth

Kulkarni Samarth has filed 19 Form 4 transactions reported between December 18, 2025 and June 26, 2026, as a reporting owner of Black Diamond Therapeutics, Inc., Director of Centessa Pharmaceuticals plc, Director of Oruka Therapeutics, Inc. and Chief Executive Officer of CRISPR Therapeutics AG.

Name as filed: Kulkarni Samarth

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$7.0M
7 lines
Companies
4
with Form 4 filings
Latest transaction
Jun 26, 2026
transaction date

Roles and reported holdings

  • BDTXBlack Diamond Therapeutics, Inc.
    Jun 26, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • CNTACentessa Pharmaceuticals plc
    Jun 24, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • ORKAOruka Therapeutics, Inc.
    Jun 2, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • CRSPCRISPR Therapeutics AG
    Dec 18, 2025 – Mar 23, 2026

    Chief Executive Officer

    Held directly255,501 sh as of Mar 23, 2026 · Form 4

    24 months: $7.0M sold

Transaction history

All 19 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Jun 26, 2026BDTXGrant or awardCode A · direct40,000—Form 4
Jun 24, 2026CNTADirectorDisposition to issuerCode D · direct40,000—Form 4
Jun 24, 2026CNTADirectorDisposition to issuerCode D · direct48,000—Form 4
Jun 24, 2026CNTADirectorDisposition to issuerCode D · direct208,474—Form 4
Jun 2, 2026ORKADirectorGrant or awardCode A · direct9,136—Form 4
Mar 23, 2026CRSPChief Executive OfficerOpen-market saleCode S · direct10,020$469K@ $46.78Form 4
Mar 20, 2026CRSPChief Executive OfficerGrant or awardCode A · direct81,875—Form 4
Mar 20, 2026CRSPChief Executive OfficerGrant or awardCode A · direct114,249—Form 4
Mar 20, 2026CRSPChief Executive OfficerOption exerciseCode M · direct19,687—Form 4
Mar 16, 2026CRSPChief Executive OfficerOpen-market saleCode S · direct10,349$499K@ $48.26Form 4
Mar 14, 2026CRSPChief Executive OfficerOption exerciseCode M · direct20,625—Form 4
Mar 11, 2026CRSPChief Executive OfficerOpen-market saleCode S · direct9,798$517K@ $52.80Form 4
Mar 10, 2026CRSPChief Executive OfficerOption exerciseCode M · direct19,250—Form 4
Feb 19, 2026CRSPChief Executive OfficerOpen-market saleCode S · direct6,967$366K@ $52.58Form 4
Feb 18, 2026CRSPChief Executive OfficerOption exerciseCode M · direct13,250—Form 4
Jan 22, 2026CRSPChief Executive OfficerOpen-market saleCode S · direct60,000$3.6M@ $60.23Form 4
Jan 20, 2026CRSPChief Executive OfficerOpen-market saleCode S · direct8,567$446K@ $52.10Form 4
Jan 20, 2026CRSPChief Executive OfficerOpen-market saleCode S · direct21,433$1.1M@ $51.61Form 4
Dec 18, 2025CRSPChief Executive OfficerGiftCode G · direct30,000—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.